Ixazomib Citrate is a prodrug of ixazomib, a protease inhibitor used in cancer research when studing multiple myleoma. When in its biologically active form, ixazomib can inhibit angiogensis and induce apoptosis by activating apoptotic pathways and upregulating tumor-suppressor genes.
| Mechanism of Action | Ixazomib is able to inhibit the chymotrypsin-like proteolytic (β5) site of the 20S proteasome, and at higher concentrations inhibit the caspase-like (β1) and trypsin-like (β2) proteolytic sites. |
| Molecular Formula | C20H23BCl2N2O9 |
| References | Offidani M et al (2014) An evidence-based review of Ixazomib Citrate and its potential in the treatment of newly diagnosed multiple myeloma. OncoTargets and Therapy, 1793. doi:10.2147/ott.s49187 |
